• Preclinical data shows improvements in response for the combination of imatinib mesylate (IM, Gleevec) and gemcitabine (GEM) therapy compared with GEM alone. (aacrjournals.org)
  • Patients receive oral imatinib mesylate twice daily on days 1-28. (knowcancer.com)
  • Imatinib mesylate and AMN107 are tyrosine kinase inhibitors that inhibit fibroblast proliferation and collagen production in lungs and skin. (eur.nl)
  • This study was conducted to determine whether imatinib mesylate and AMN107 inhibit orbital fibroblast proliferation and hyaluronan production induced by PDGF-BB and TGF-β1and whether expression of the genes PDGF-B and TGF-B1(growth factors suggested to play a role in GO) are increased in GO orbital tissues. (eur.nl)
  • Orbital fibroblasts were cultured from eight patients with GO and three control patients and the effect of imatinib mesylate and AMN107 on PDGF-BB and TGF-β1-induced orbital fibroblast proliferation, signaling cascades, hyaluronan synthase (HAS) gene expression and hyaluronan production were determined. (eur.nl)
  • Imatinib mesylate and AMN107 inhibited PDGF-BB-induced orbital fibroblast proliferation, HAS induction and hyaluronan production by blocking PDGFreceptor phosphorylation. (eur.nl)
  • This induction was not inhibited by imatinib mesylate or AMN107, due to the inability of TGF-β1to activate c-Abl kinase activity in orbital fibroblasts. (eur.nl)
  • Nevertheless, imatinib mesylate and AMN107 should be considered as treatment candidates for GO. (eur.nl)
  • Requests for investigator-initiated trials have been granted for COVID-19-related clinical studies of ruxolitinib, canakinumab, imatinib mesylate, secukinumab, hydroxychloroquine and valsartan. (novartis.com)
  • According to IQVIA, US sales of Imatinib Mesylate Tablets were approximately $831 million in the 12 months ending August 2018. (hikma.com)
  • Imatinib mesylate is often associated with edema and occasionally serious fluid retention. (hikma.com)
  • 65 years) or those taking higher doses of imatinib mesylate. (hikma.com)
  • Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib mesylate, and in 2%-6% of other adult CML patients taking imatinib mesylate. (hikma.com)
  • In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking imatinib mesylate, and in 2%-6% of other adult CML patients taking imatinib mesylate. (hikma.com)
  • In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib mesylate and nilotinib, severe (Grade 3 or 4) fluid retention occurred in 2.5% of patients receiving imatinib mesylate and in 3.9% of patients receiving nilotinib 300 mg twice daily. (hikma.com)
  • Effusions (including pleural effusion, pericardial effusion, ascites) or pulmonary edema were observed in 2.1% (none were Grade 3 or 4) of patients in the imatinib mesylate arm and 2.2% (0.7% Grade 3 or 4) of patients in the nilotinib 300 mg twice daily arm. (hikma.com)
  • Preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia patients taking the drug Imatinib mesylate (Gleevec). (sciencedaily.com)
  • The CHMP also backed approval of Bristol-Myers Squibb's Sprycel (dasatinib) for the treatment of chronic myeloid leukaemia in patients with resistance or intolerance to prior therapy including Novartis' Glivec (imatinib mesylate), and acute lymphoblastic leukaemia in patients with resistance or intolerance to prior therapy. (pharmatimes.com)
  • BACKGROUND: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is a tyrosine kinase inhibitor that targets those proteins involved in BCR-ABL signal transduction in CML, c-kit (KIT) and platelet-derived growth-factor (PDGFR) receptor. (unipv.it)
  • Imatinib mesylate, a small-molecule inhibitor of the KIT tyrosine kinase, provides a rapid but not durable clinical response in KIT-mutant melanoma. (elsevierpure.com)
  • Herein, we designed clinical trial of co-administrating imatinib mesylate and pembrolizumab (anti-PD-1 antibody) to evaluate its safety and efficacy.Methods and analysis:This is an open-label, single-arm, phase I/II clinical trial involving Japanese patients with metastatic KIT-mutant melanoma that are refractory to standard therapy including anti-PD-1 therapy. (elsevierpure.com)
  • Phase I study is a dose-escalation study comprising two dose levels of imatinib mesylate (200 and 400 mg/day, respectively) with fixed dose of pembrolizumab (200 mg every 3 weeks) to evaluate safety and tolerability and determine recommended phase II dose. (elsevierpure.com)
  • The primary endpoint of the phase II study is the objective response rate after 4 cycles (3 weeks/cycle) of pembrolizumab and imatinib mesylate at the dose determined in phase I, based on RECIST version 1.1. (elsevierpure.com)
  • Tasigna demonstrated that significantly fewer patients progressed to more advanced stages of the disease than the standard of care Gleevec (imatinib mesylate) tablets* at 12 months. (salesandmarketingnetwork.com)
  • The introduction of imatinib, a selective inhibitor of the ABL tyrosine kinase, has revolutionized the treatment and the outcome of this subset of patients [ 1 ]. (hindawi.com)
  • However, a substantial proportion of imatinib-treated Ph+ ALL patients develop resistance to imatinib. (hindawi.com)
  • Second-generation TKIs have demonstrated promising efficacy in the treatment of imatinib-resistant Ph+ ALL patients, but despite these results, the relapse rate of Ph+ ALL patients remains very high with an overall survival still unsatisfactory [ 2 ]. (hindawi.com)
  • Recently "natural" bcr-abl breakpoint-specific cytotoxic T lymphocytes (CTLs) were found in the bone marrow of Ph+ ALL patients treated with imatinib correlating with a better response to this TKI [ 6 ]. (hindawi.com)
  • Previously, we have developed a p210-breakpoint derived penta-peptide vaccine for controlling minimal residual disease in Chronic Myeloid Leukemia (CML) patients treated with imatinib [ 7 ]. (hindawi.com)
  • Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. (tau.ac.il)
  • Of clinical relevance, we identify that combination of 1C metabolism inhibition with imatinib, a frontline treatment for CML patients, decreases the number of therapy-resistant CML LSCs in a patient-derived xenograft model. (bvsalud.org)
  • They also looked at three drugs for chronic myeloid leukemia: dasatinib (Sprycel), imatinib mesylate (Gleevec), and nilotinib hydrochloride monohydrate (Tasigna). (medscape.com)
  • To determine the frequency and severity of adverse effects of Gleevec in this cohort of patients as assessed by CTC. (knowcancer.com)
  • Gleevec, one of the first targeted cancer therapies with wide success in CML patients, destroys most leukemic cells in the body, but in most patients, some cancerous cells remain and are measurable with sensitive molecular tests. (sciencedaily.com)
  • The study vaccine was given to 19 CML patients with measurable cancer cells, despite taking Gleevec for at least one year. (sciencedaily.com)
  • According to the investigators, most patients with CML will need to remain on Gleevec therapy for the rest of their lives. (sciencedaily.com)
  • Gleevec also cannot be taken during pregnancy, and since one-third of CML patients are in their 20s and 30s, many patients hoping to start families would like to discontinue taking it. (sciencedaily.com)
  • Ultimately, should this vaccine approach prove to be successful, the ability to get patients off lifelong Gleevec therapy would be a significant advance," says Levitsky. (sciencedaily.com)
  • All filings are based on data showing superior efficacy for Tasigna in the first head-to-head comparison of the drug against the standard of care Gleevec in newly diagnosed Ph+ CML patients. (salesandmarketingnetwork.com)
  • If approved for the first-line indication, Tasigna will be the first drug for newly diagnosed patients to become available since the approval of Gleevec in 2002. (salesandmarketingnetwork.com)
  • Recently presented data showed that Tasigna surpassed Gleevec in every measure of treatment efficacy designated in the study including prevention of disease progression at 12 months," said David Epstein, CEO of the Novartis Pharmaceuticals Division. (salesandmarketingnetwork.com)
  • This randomized, open-label, multicenter trial compared the efficacy and safety of Tasigna versus Gleevec in adult patients with newly diagnosed Ph+ CML in chronic phase(1). (salesandmarketingnetwork.com)
  • In the ENESTnd clinical trial significantly fewer patients at 12 months progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Gleevec 400 mg once daily (2 patients vs. 11 patients)(1), demonstrating a significant improvement in disease control. (salesandmarketingnetwork.com)
  • Fewer patients discontinued due to adverse events from the Tasigna 300 mg twice daily arm of the study compared to the Gleevec 400 mg once daily arm. (salesandmarketingnetwork.com)
  • Tasigna has been approved in more than 80 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. (salesandmarketingnetwork.com)
  • Purpose: This dose-ranging trial of intravenous dolasetron mesylate (MDL73, 147EF) was performed to determine its adverse and antiemetic effects in patients receiving cisplatin at doses ≥ 100 mg/m 2 . (elsevierpure.com)
  • Patients and Methods: Eighty-nine patients treated with initial cisplatin received a single intravenous dose of dolasetron mesylate administered over 20 minutes beginning 30 minutes before chemotherapy. (elsevierpure.com)
  • Conclusion: Dolasetron mesylate can be administered safely at doses up to 5.0 mg/kg, with comparable complete protection rates and increased adverse effects at doses greater than 2.4 mg/kg. (elsevierpure.com)
  • Trials comparing single infusions of dolasetron mesylate and ondansetron are under way. (elsevierpure.com)
  • Anzemet has active ingredients of dolasetron mesylate . (ehealthme.com)
  • It is based on dolasetron mesylate (the active ingredients of Anzemet) and Anzemet (the brand name). (ehealthme.com)
  • D.H.E. 45 (dihydroergotamine mesylate) is an ergot alkaloid used to treat a migraine or cluster headache attack. (rxlist.com)
  • Our D.H.E. 45 (dihydroergotamine mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • D.H.E. 45® (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. (rxlist.com)
  • D.H.E. 45® (dihydroergotamine mesylate) Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. (rxlist.com)
  • Available as a clear, colorless, sterile solution in single 1 mL sterile ampuls containing 1 mg of dihydroergotamine mesylate per mL, in packages of 10 (NDC 0078-0041-01). (rxlist.com)
  • Serious cardiac events, including some that have been fatal, have occurred following use of D.H.E. 45® (dihydroergotamine mesylate) Injection, USP, but are extremely rare. (rxlist.com)
  • Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. (mobilehealthtimes.com)
  • Using Impel's proprietary Precision Olfactory Delivery (POD) technology, TRUDHESA gently delivers dihydroergotamine mesylate (DHE) quickly to the bloodstream through the vascular-rich upper nasal space. (mobilehealthtimes.com)
  • We are donating hydroxychloroquine tablets for COVID-19 patients including for use in this and other clinical trials with the hope that researchers and healthcare workers can quickly and scientifically determine whether hydroxychloroquine can help patients around the world combat this disease," said Richard Saynor, CEO of Sandoz. (novartis.com)
  • METHODS: This was a 1-yr retrospective cohort study involving all COVID-19 patients admitted to intensive care units in six hospitals affiliated with Yale New Haven Health System from February 13, 2020, to March 4, 2021. (bvsalud.org)
  • MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE were searched in February 2021 for controlled studies. (bvsalud.org)
  • EAST HANOVER, N.J., Feb. 19 -- (Healthcare Sales & Marketing Network) -- Novartis announced today that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (salesandmarketingnetwork.com)
  • The regulatory submissions are based on data from the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients) Phase III clinical trial. (salesandmarketingnetwork.com)
  • Sudden deaths have been reported in patients receiving nilotinib. (salesandmarketingnetwork.com)
  • In all three studies, doxazosin mesylate resulted in statistically significant relief of obstructive and irritative symptoms compared to placebo. (nih.gov)
  • Statistically significant improvements of 2.3 to 3.3 mL/sec in maximum flow rate were seen with doxazosin mesylate in STUDIES 1 and 2 , compared to 0.1 to 0.7 mL/sec with placebo. (nih.gov)
  • Before the advent of tyrosine kinase inhibitors (TKIs), the outcome of Ph+ ALL patients not eligible for allogeneic stem cell transplant (allo-SCT) was characterized by an extremely poor prognosis, a weak response to most chemotherapy combinations, short remission durations, and poor survival rates. (hindawi.com)
  • The efficacy of doxazosin mesylate was evaluated extensively in over 900 patients with BPH in double-blind, placebo-controlled trials. (nih.gov)
  • Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. (elsevierpure.com)
  • The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. (mayo.edu)
  • A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study) Rochester, Minn. This study seeks adult subjects with R/R Ph+ B-precursor ALL. (mayo.edu)
  • Totally, a target size of 22 patients will be expected.Discussion:If this study shows efficacy and acceptable safety profile, it will contribute to the development of novel treatment option for patients with KIT-mutant melanoma that are refractory to standard therapy.Trial registration:NCT04546074. (elsevierpure.com)
  • Exploratory objectives included efficacy assessments of migraine measures and a patient acceptability questionnaire. (mobilehealthtimes.com)
  • In the STOP 301 study, patient-reported exploratory efficacy findings reported that more than a third of patients (38%) had pain freedom, two-thirds (66%) had pain relief, and more than half (52%) had freedom from their most bothersome migraine symptom at two hours after their first dose of TRUDHESA. (mobilehealthtimes.com)
  • We identified one peptide named p190-13 able to induce in vitro peptide-specific CD4+ T cell proliferation in Ph+ ALL patients in complete remission during TKIs. (hindawi.com)
  • This study demonstrates an additional cellular target of IM, not necessarily mediated via known tyrosine kinases, that causes inhibition of TA and cell proliferation. (tau.ac.il)
  • In the present study, it was investigated whether the treatment of cancer cells with IM (an inhibitor of oxidative phosphorylation) separately, or together with dichloroacetate (DCA) (an inhibitor of glycolysis), can inhibit cell proliferation or cause death. (bvsalud.org)
  • This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy. (rochester.edu)
  • Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. (medscape.org)
  • A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL Rochester, Minn., Jacksonville, Fla. (mayo.edu)
  • This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. (mayo.edu)
  • In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. (bvsalud.org)
  • Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. (cancercentrum.se)
  • A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial. (cdc.gov)
  • In a Phase III study, lomitapide led to elevated aminotransferase levels and fat accumulation in the liver. (wikipedia.org)
  • Basel, April 20, 2020 - Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. (novartis.com)
  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (hikma.com)
  • Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy. (hikma.com)
  • A phase 1 study of AZD6244 in children with recurrent or refractory low grade gliomas: a pediatric brain tumor consortium report. (medscape.org)
  • A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. (medscape.org)
  • Phase II study of binimetinib in children and adults with NF1 plexiform neurofibromas (NF108-BINI). (medscape.org)
  • Selumetinib in paediatric patients with BRAF -aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicenter, phase 2 trial. (medscape.org)
  • Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. (medscape.org)
  • Trametinib in pediatric patients with neurofibromatosis type 1-associated plexiform neurofibroma: a phase I/II study. (medscape.org)
  • Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 3 study on the benefits of a combination therapy to treat patients with untreated locally advanced or metastatic urothelial cancer. (cityofhope.org)
  • Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 2 study on the benefits of atezolizumab, with or without eribulin mesylate, in treating patients with urothelial cancer that has come back, or spread to nearby tissues and lymph nodes, or other places in the body. (cityofhope.org)
  • Sumanta Pal, M.D., is actively recruiting patients for a Phase 3 trial studying the benefits of an oral targeted therapy for the adjuvant treatment of patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations that is considered high risk for recurrence with surgery alone. (cityofhope.org)
  • A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) Jacksonville, Fla., Rochester, Minn. (mayo.edu)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • Now this priority review designation brings us one step closer to offering patients who are newly diagnosed with Ph+ CML in the chronic phase a promising new treatment option. (salesandmarketingnetwork.com)
  • The phase IV clinical study analyzes which people take Anzemet and have Tachypnea. (ehealthme.com)
  • The New Drug Application for TRUDHESA included the results of the Phase 3, open-label, pivotal safety study, STOP 301, which is the largest longitudinal study ever conducted with DHE using nasal spray delivery. (mobilehealthtimes.com)
  • Boehringer Ingelheim presented positive results of its Phase 3 RE-VERSE AD study for idarucizumab as a reversal agent for the anticoagulant effect of Pradaxa (dabigatran) in patients needing emergency surgery or for life-threatening or uncontrolled bleeding events. (empr.com)
  • Boehringer Ingelheim announced results from an interim analysis of the Phase 3 RE-VERSE AS patient study with idarucizumab for urgent reversal of the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate). (empr.com)
  • See dosage adjustment recommendations if coadministered in treatment-experienced patients. (medscape.com)
  • Dosage of drugs is not considered in the study. (ehealthme.com)
  • MitoQ may be a useful therapeutic agent to preserve diaphragm function in critically ill patients with sepsis. (uky.edu)
  • Moreover, LCMV may cause severe disease in immunosuppressed patients and can constitute a threat to pregnant woman and their unborn children. (dpz.eu)
  • The reason older patients and males show increased risk of severe disease and death remains uncertain. (mdpi.com)
  • The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. (elsevierpure.com)
  • Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. (elsevierpure.com)
  • Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19. (elsevierpure.com)
  • In adult patients for short term management of severe hypertension when rapid and reversible reduction of blood pressure is clinically indicated, including for malignant hypertension with deteriorating end-organ function ( 1.1 ). (pfizermedicalinformation.com)
  • CONCLUSIONS: Consistent with the known hypercoagulability in severe COVID-19, the use of apixaban, enoxaparin, or aspirin was independently associated with lower mortality in critically ill COVID-19 patients. (bvsalud.org)
  • 2 in ARISTOTLE, patients with clinically significant (moderate or severe) mitral stenosis, or prosthetic mechanical heart valve. (acc.org)
  • Multilevel determinants of racial/ethnic disparities in severe maternal morbidity and mortality in the context of the COVID-19 pandemic in the USA: protocol for a concurrent triangulation, mixed-methods study. (cdc.gov)
  • The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for idarucizumab (Boehringer Ingelheim) to reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients needing emergency intervention or experiencing an uncontrolled or life-threatening bleeding event. (empr.com)
  • Boehringer Ingelheim announced that the FDA has accepted for filing the supplemental New Drug Application (sNDA) for Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had primary elective total hip replacement surgery. (empr.com)
  • Boehringer Ingelheim announced that it has submitted a Biologics License Application (BLA) to the FDA, requesting accelerated approval for the use of idarucizumab to reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate). (empr.com)
  • The FDA has granted Breakthrough Therapy designation to idarucizumab (Boehringer Ingelheim), an investigational fully humanized antibody fragment (Fab), being evaluated as a specific antidote for Pradaxa (dabigatran etexilate mesylate). (empr.com)
  • Boehringer Ingelheim announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). (empr.com)
  • As a result of the landmark clinical trials RE-LY, 1 ROCKET AF, 2 and ARISTOTLE, 3 which compared warfarin to a novel oral anticoagulant-dabigatran, rivaroxaban, or apixaban, respectively-the pharmacological options for managing stroke risk in patients with non-valvular atrial fibrillation (NVAF) have expanded. (acc.org)
  • Monitoring renal function is of particular importance in patients on dabigatran (80% renal clearance). (acc.org)
  • The objective of this study is to assess the safety and tolerability, including the maximum tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). (mayo.edu)
  • The primary objective of the study was to assess the safety and tolerability of TRUDHESA. (mobilehealthtimes.com)
  • The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
  • In a clinical study of 12 patients with open-angle glaucoma or ocular hypertension (mean baseline intraocular pressure was 29.2 mm Hg with a range of 22 to 33 mm Hg), infusion of fenoldopam at escalating doses ranging from 0.05 to 0.5 mcg/kg/min over a 3.5 hour period caused a dose-dependent increase in intraocular pressure (IOP). (pfizermedicalinformation.com)
  • Supporting Structured Data Capture for Patients With Cancer: An Initiative of the University of Wisconsin Carbone Cancer Center Survivorship Program to Improve Capture of Malignant Diagnosis and Cancer Staging Data. (rochester.edu)
  • Patients with oral malignant melanoma often recall having an existing oral pigmentation months to years before diagnosis, and the condition may even have elicited prior comment from examining physicians and dentists (or healthcare providers, when considering the auxiliaries). (medscape.com)
  • Pauniaho SL, Salonen J, Helminen M, Vettenranta K, Heikinheimo M, Heikinheimo O. The incidences of malignant gonadal and extragonadal germ cell tumors in males and females: a population-based study covering over 40 years in Finland. (cancercentrum.se)
  • Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. (cancercentrum.se)
  • Considering that only few patients with gastrointestinal stromal tumors have been reported in the obstetrical and gynecological literature, the awareness of such an entity by the obstetricians-gynecologists is necessary in order to facilitate coordinated approach with the general surgeons and oncologists for the optimal care of the patients. (scirp.org)
  • This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. (cancerindex.org)
  • Mayr D, Hirschmann A, Marlow S, Horvath C, Diebold J. Analysis of selected oncogenes (AKT1, FOS, BCL2L2, TGFbeta) on chromosome 14 in granulosa cell tumors (GCTs): a comprehensive study on 30 GCTs combining comparative genomic hybridization (CGH) and fluorescence-in situ-hybridization (FISH). (cancercentrum.se)
  • SEE NAMCS PATIENT DATASET NAMES FOR DSN ABSTRACT General Information This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Survey (NAMCS) conducted by the National Center for Health Statistics. (cdc.gov)
  • Adult patients with unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP). (hikma.com)
  • Patients must have no evidence of metastatic disease based on screening computed tomography or magnetic resonance imaging. (cityofhope.org)
  • Patients with metastatic disease (most commonly to the liver) may also be candidates for surgery depending on the degree of liver involvement, tumor size, and surgical resectability. (msdmanuals.com)
  • Adult patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). (hikma.com)
  • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test. (hikma.com)
  • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown. (hikma.com)
  • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (hikma.com)
  • Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019). (lu.se)
  • In the human prostate, doxazosin mesylate antagonizes phenylephrine (alpha 1 agonist)-induced contractions, in vitro , and binds with high affinity to the alpha 1c adrenoceptor. (nih.gov)
  • Doxazosin mesylate is a quinazoline compound that is a selective inhibitor of the alpha 1 subtype of alpha adrenergic receptors. (nih.gov)
  • Because alternatives to the use of rifampin for antituberculosis treatment are now available, the previously recommended practice of stopping protease inhibitor therapy to allow the use of rifampin for TB treatment is no longer recommended for patients with HIV-related TB. (cdc.gov)
  • GEODON is available as capsules (ziprasidone hydrochloride) for oral administration and as an injection (ziprasidone mesylate) for intramuscular use only. (rxlist.com)
  • The following four dose levels were studied: 1.8, 2.4, 3.0, and 5.0 mg/kg. (elsevierpure.com)
  • OBJECTIVE: The aim of this study is to evaluate the effects of IM therapy on the skin pigmentation of five patients affected by CML. (unipv.it)
  • Each doxazosin mesylate tablet, for oral administration, contains 1 mg, 2 mg, 4 mg, or 8 mg of doxazosin as the free base. (nih.gov)
  • The drug hydroxychloroquine has garnered interest in the medical community after showing preliminary promise in small clinical studies, including one with co-administration with the antibiotic azithromycin. (novartis.com)
  • We hypothesized that administration of mitoquinone mesylate (MitoQ), a mitochondrially targeted free radical scavenger, would prevent sepsis-induced diaphragm dysfunction. (uky.edu)
  • All HIV-infected patients undergoing treatment for TB should be evaluated for antiretroviral therapy, because most patients with HIV-related TB are candidates for concurrent administration of antituberculosis and antiretroviral drug therapies. (cdc.gov)
  • Patients receiving the trial vaccine experienced relatively few side effects that included injection site pain and swelling, occasional muscle aches and mild fevers. (sciencedaily.com)
  • Geodon (ziprasidone HCl) is available as capsules and Geodon (ziprasidone mesylate) is available as an injection for intramuscular use. (rxlist.com)
  • Eli Lilly and Amylin moved a step closer to securing European Medicines Agency approval for their fast-growing drug Byetta yesterday, after the Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on its use in patients with type 2 diabetes. (pharmatimes.com)
  • Since alpha 1 adrenoceptors are of low density in the urinary bladder (apart from the bladder neck), doxazosin mesylate should maintain bladder contractility. (nih.gov)
  • In three placebo-controlled studies of 14 to 16 weeks duration obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning) of BPH were evaluated at each visit by patient-assessed symptom questionnaires. (nih.gov)
  • Our world-class experts offer bladder cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies. (cityofhope.org)
  • Boehringer Ingelheim) in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE). (empr.com)
  • We do not know yet how to select patients for this therapy and how to move it from life extension to cure. (aacrjournals.org)
  • Byetta (exenatide) is an incretin mimetic that is an add-on therapy, used in patients with type 2 diabetes whose blood glucose levels aren't controlled with oral diabetes agents such as metformin or sulfonylureas. (pharmatimes.com)
  • In the last 2 years numerous studies have focused the attention on hypopigmentations, depigmentations and photosensitivity developing after the initiation of IM therapy. (unipv.it)
  • The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care. (mayo.edu)
  • 1-9 However, OS for the St. Jude Total Therapy Study XVI (94.3%) was similar to that for the Total Therapy Study XV (93.5%) ( Figure 1 ). (haematologica.org)
  • A randomized trial of 16 808 postmenopausal women receiving hormone replacement therapy (HRT) versus placebo demonstrated that HRT-treated patients experienced an increase in major adverse events, such as breast cancer, venous thromboembolism, and cardiovascular events. (allenpress.com)
  • The great majority of patients (84%) reported that TRUDHESA was easy to use 10 and preferred it over their current therapy. (mobilehealthtimes.com)
  • Ideally, the management of TB among HIV-infected patients taking antiretroviral drugs requires a) directly observed therapy, b) availability of experienced and coordinated TB/HIV care givers, and in most situations, c) use of a TB treatment regimen that includes rifabutin instead of rifampin. (cdc.gov)
  • Physicians and patients also should be aware that paradoxical reactions might occur during the course of TB treatment when antiretroviral therapy restores immune function. (cdc.gov)
  • Adding to CDC's current recommendations for administering isoniazid preventive therapy to HIV-infected persons with positive tuberculin skin tests and to HIV-infected persons who were exposed to patients with infectious TB, this report also describes in detail the use of new short-course (i.e., 2 months) multidrug regimens (e.g., a rifamycin, such as rifampin or rifabutin, combined with pyrazinamide) to prevent TB in persons with HIV infection. (cdc.gov)
  • Novartis plans to begin enrollment for this study within the next few weeks and is committed to reporting results as soon as possible. (novartis.com)
  • We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease," said John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. (novartis.com)
  • As part of its research and development commitment, Novartis has formed a clinical investigation team to provide rapid access for approved clinical requests and support of clinical evaluation of its medicines to be repurposed and address the needs of patients with COVID-19 infections. (novartis.com)
  • In addition to hydroxychloroquine, Novartis plans to sponsor or co-sponsor clinical trials to study ruxolitinib and canakinumab for hospitalized patients with COVID-19 infections. (novartis.com)
  • Sepsis-induced diaphragm dysfunction is a major contributor to respiratory failure in mechanically ventilated patients. (uky.edu)
  • NEW & NOTEWORTHY This is the first study to show that mitoquinone mesylate (MitoQ), a mitochondrially targeted antioxidant, treats sepsis-induced skeletal muscle dysfunction. (uky.edu)
  • When leukemic blasts replace the bone marrow, patients present with signs of bone marrow failure, including anemia, thrombocytopenia, and neutropenia. (medscape.com)
  • The commonest treatment for thalas- sion in thalassaemia patients with some saemia patients, apart from bone marrow degree of systolic function impairment. (who.int)
  • We mobilized quickly to address this question in a randomized, double-blind, placebo-controlled study. (novartis.com)
  • To expand knowledge and understanding in this area, there is a need for consensus on a definition of osteosarcopenic obesity which will allow for identification, further epidemiological studies and comparisons between studies. (springer.com)
  • Patients who have recovered from coronavirus disease 2019 (COVID-19) infection may experience chronic fatigue when exercising, despite no obvious heart or lung abnormalities. (mdpi.com)
  • however, after a trial suggesting an association between HRT and a number of serious adverse events, alternative therapies for VMS are being studied. (allenpress.com)
  • There were no serious TRUDHESA-related treatment-emergent adverse events (TEAEs) observed in the STOP 301 study and the majority of TEAEs were mild and transient in nature. (mobilehealthtimes.com)
  • The drug infusion was discontinued in patients devel- oping all these adverse effects. (who.int)
  • Diagnosis is based on histology and immunohistochemistry, while the role of imaging studies is not specific. (scirp.org)
  • PATIENTS AND METHODS: Ten blood samples were obtained from two groups of patients diagnosed with CML: those at the initial diagnosis stage and those at the recurrence stage. (bvsalud.org)
  • Early diagnosis and effective treatment of TB among HIV-infected patients are critical for curing TB, minimizing the negative effects of TB on the course of HIV, and interrupting the transmission of Mycobacterium tuberculosis to other persons in the community. (cdc.gov)
  • It is the largest global randomized comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients. (salesandmarketingnetwork.com)
  • Clinicians should opt for safety and consider prescribing warfarin in patients with marginal renal function. (acc.org)
  • Doxazosin mesylate acts within 1 to 2 weeks to decrease the severity of BPH symptoms and improve urinary flow rate. (nih.gov)
  • Doxazosin mesylate treatment was superior to placebo in improving patient symptoms and urinary flow rate. (nih.gov)
  • In 66 to 71% of patients, improvements above baseline were seen in both symptoms and maximum urinary flow rate. (nih.gov)
  • Weigh and monitor patients regularly for signs and symptoms of fluid retention. (hikma.com)
  • Conclusion: In the patients with a pelvic mass, especially if unusual symptoms and laboratory data being not compatible with gynecological disease, the possibility of diseases other than a gynecologic disease has to be considered. (scirp.org)
  • Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms in susceptible patients ( 5.4 ). (pfizermedicalinformation.com)
  • There are conflicting data regarding the use of SSRIs and SNRIs for patients with vasomotor symptoms related to menopause, and these agents may not be ideal for all patients. (allenpress.com)
  • Geodon (ziprasidone HCl and ziprasidone mesylate) is an atypical antipsychotic used to treat symptoms of schizophrenia and acute manic or mixed episodes associated with bipolar disorder . (rxlist.com)
  • results: All the studied patients show the gradual lightening of the skin on unexposed areas over the treatment with IM. (unipv.it)
  • Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet , Mayo Clinic Proceedings , and Nature . (ehealthme.com)
  • RESULTS: This study analyzed 2,070 patients after excluding 23 patients who died within 24 h after intensive care unit admission and 3 patients who remained hospitalized on the last day of data censoring. (bvsalud.org)
  • Thus, it is important to understand the patient populations, design, and results from these trials to guide clinical practice. (acc.org)
  • Clinicians must be aware that patients in RE-LY, ROCKET AF, and ARISTOTLE were highly selected and therefore the trial results may not be applicable to all patients with atrial fibrillation (AF) in their practice.1-4 Baseline characteristics for the study populations are displayed in Table I. (acc.org)
  • Results varied for individual medicines in the study. (medscape.com)
  • Still, the results highlight the potential for company payments to influence doctors' treatment decisions, said Dr. Yoram Unguru of the Johns Hopkins Berman Institute of Bioethics in Baltimore, who wasn't involved in the study. (medscape.com)
  • Many of my patients need more from their migraine treatment, and TRUDHESA offers a non-oral, fast-acting, reliable option that overcomes many current medication challenges," said Stephanie J. Nahas-Geiger, MD, MSEd, Associate Professor in the Department of Neurology, and Program Director of the Headache Medicine Fellowship Program, Thomas Jefferson University. (mobilehealthtimes.com)
  • Vitamin K antagonists are the only oral anticoagulants approved for long-term anticoagulation in patients with mechanical or biological prosthetic heart valves or hemodynamically significant mitral stenosis. (acc.org)
  • More than 90 percent of them will achieve remission, but about 10 to 15 percent of patients cannot tolerate the drug long term. (sciencedaily.com)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • Cytogenetic studies reveal specific abnormalities in DFSP tumor cells, such as reciprocal translocations of chromosomes 17 and 22, t(17;22), and supernumerary ring chromosomes composed of interspersed sequences from bands 17(17q22) and 22(22q12). (medscape.com)
  • The incidence of DFSP has been estimated to be 0.8-5 case per million population per year in 2 separate studies. (medscape.com)
  • [ 2 ] In a another study based on data from 9 cancer registries from 1973-2002, the annual incidence of DFSP in the United States is 4.2 cases per million population per year. (medscape.com)
  • [ 10 ] A study of the population-based National Cancer Registry shows the incidence of DFSP is approximately 4 cases per million per year in Sweden from 1990-2005. (medscape.com)
  • Often patients have low blood cell counts, fluid retention, significant nausea and other gastrointestinal problems," says B. Douglas Smith, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center. (sciencedaily.com)
  • While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. (elsevierpure.com)
  • A Study of Advanced Practice Provider Staffing Models and Professional Development Opportunities at National Comprehensive Cancer Network Member Institutions. (rochester.edu)
  • In a pilot study published in Clinical Cancer Research , the Johns Hopkins investigators used a vaccine made from CML cells irradiated to halt their cancerous potential and genetically altered to produce an immune system stimulator called GM-CSF. (sciencedaily.com)
  • After a median of 72 months of follow-up, the number of remaining cancer cells declined in 13 patients, 12 of whom reached their lowest levels of residual cancer cells. (sciencedaily.com)
  • Reuters Health) - Some oncologists may be more likely to prescribe certain cancer medicines when they receive payments from the companies that make these drugs, a U.S. study suggests. (medscape.com)
  • While others have studied industry payments in relation (to) prescribing of other kinds of drugs, like blood pressure and cholesterol medications, ours is the first study examining oncology drugs," said senior study author Stacie Dusetzina, a researcher at Vanderbilt University Medical Center and the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. (medscape.com)
  • The study wasn't a controlled experiment designed to prove whether or how research funding or other payments from drug companies directly influences the medicines doctors prescribe for cancer. (medscape.com)
  • In long-term studies improvement was maintained for up to 2 years of treatment. (nih.gov)
  • As the new virus continues to spread and claim lives around the globe, doctors and patients are eager for treatment options. (novartis.com)
  • Patients in all treatment groups are receiving standard of care for COVID-19. (novartis.com)
  • Sprycel, which is already on the market in the USA, is considered a major new product for the group, as it should provide the first treatment option for the 30% of patients with CML who fail to respond to Glivec, itself a blockbuster product. (pharmatimes.com)
  • For treatment-naïve patients, take atazanavir simultaneously with the H2RA or at least 10 h afterwards. (medscape.com)
  • I think patients will be very receptive to this treatment, because it pairs the long-proven benefits of DHE with a patient-friendly delivery system. (mobilehealthtimes.com)
  • Study selection criteria were randomized trials comparing aspirin for prevention of all gestational age and preterm preeclampsia to placebo or no antiplatelet treatment in women aged 15-55 years with moderate or high-risk factors according to the list of risk factors from American College of Obstetricians and Gynecologists and United States Preventive Services Task Force guidelines. (bvsalud.org)
  • Haemosiderosis, which plays a considerable function in thalassaemia patients before and role in early mortality, can be prevented or after treatment with high-dose deferoxam- postponed by iron-chelating agents which ine. (who.int)
  • Efforts have been made to establish a the patients to determine pulse rate interval, safe treatment of cardiac complications in QRS duration, arrhythmia and systolic and thalassaemia patients. (who.int)
  • However, some patients may experience fewer favorable outcomes and treatment resistance. (bvsalud.org)
  • Over the past 60 years, due to the advancement of hemo- the Work Group and tasked it with planning, developing, dialysis (HD) technology and the introduction of medical reviewing, and disseminating appropriate HD treatment insurance, dialysis treatment has become widespread, en- guidelines in accordance with international standards. (bvsalud.org)
  • 10. Participants with a history of previously treated neoplastic spinal cord compression or clinically inactive brain metastases, who require no treatment with corticosteroids or anticonvulsants may be included in the study, if they have recovered from acute toxic effects of radiotherapy. (who.int)
  • Additionally, studies should assess whether the clinical outcomes associated with osteosarcopenic obesity are worse than the mere addition of those linked with its components. (springer.com)
  • Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 and to combat this pandemic. (biorxiv.org)
  • Patients in the trial will be randomized into three groups. (novartis.com)
  • A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. (cdc.gov)
  • Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. (cdc.gov)
  • This study from the laboratory of Prof. Reichl, Max-Planck-Institute Magdeburg, shows that genetically homogenous influenza A virus defective interfering particles (DIPs) produced in cell culture can inhibit influenza A virus infection in a rodent model. (dpz.eu)
  • This study of the DPZ Infection Biology Unit shows that SARS-CoV-2 variants Beta (B.1.351) and Gamma (P.1) can partially evade neutralizing antibodies, while the antibody evasion of the Alpha variant (B.1.1.7) is inefficient. (dpz.eu)
  • Studies of the Infection Biology Unit revealed that SARS-CoV-2 uses the cellular protease for activation of its spike protein. (dpz.eu)